Breaking News Instant updates and real-time market news.

FB

Facebook

$206.90

4.42 (2.18%)

, AMZN

Amazon.com

$1,797.01

43.96 (2.51%)

07:59
07/13/18
07/13
07:59
07/13/18
07:59

Facebook price target raised to $240 from $215 at Jefferies

Jefferies analyst Brent Thill raised his price target for Facebook (FB) shares to $240 from $215 ahead of the Q2 reporting season for the Internet space. The social media giant closed yesterday up 2% to $206.98. Amazon.com (AMZN), Facebook and Google (GOOGL) are the analyst's top large-cap picks into the earnings season. Expedia (EXPE) is Thill's top value play while IAC (IAC) and GoDaddy (GDDY) are his favorite names among smaller caps. Facebook continues to be the best return on investment for advertisers as Instagram shows continued strength and more ad opportunities are being added, Thill tells investors in a research note on the Internet space. He sees earnings per share of $10-plus "on the horizon." A 25-30 times multiple off that yields a stock price of $250-$300 for Facebook, the analyst points out. Thill keeps a Buy rating on the name.

FB

Facebook

$206.90

4.42 (2.18%)

AMZN

Amazon.com

$1,797.01

43.96 (2.51%)

GOOG

Alphabet

$1,183.87

29.48 (2.55%)

GOOGL

Alphabet Class A

$1,201.91

31.16 (2.66%)

EXPE

Expedia

$127.38

2.2 (1.76%)

IAC

IAC

$155.55

3.89 (2.56%)

GDDY

GoDaddy

$76.92

1.785 (2.38%)

  • 17

    Jul

  • 18

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 26

    Jul

  • 26

    Jul

  • 02

    Aug

  • 16

    Aug

  • 06

    Sep

  • 28

    Oct

FB Facebook
$206.90

4.42 (2.18%)

07/13/18
LEHM
07/13/18
NO CHANGE
Target $226
LEHM
Overweight
Facebook price target raised to $226 from $190 at Barclays
Barclays analyst Ross Sandler maintained an Overweight rating on Facebook and raised his price target to $226 from $190, telling investors that he sees an in-line Q2 with high expectations into the print, which he believes is largely priced in. Looking ahead, Sandler says the narrative around Stories ads could be a catalyst this year and beyond, and that Q2 should see MAU and DAU "leakage" in Europe from GDPR, which he views as a non-event, but could weigh on shares in the short-term.
07/12/18
ADAM
07/12/18
NO CHANGE
Target $240
ADAM
Buy
Privacy concerns at Facebook linger, but Canaccord says 'constructive' on shares
Canaccord analyst Michael Graham maintained a Buy rating on Facebook (FB) shares ahead of the company's quarterly earnings, telling investors in a research note that he is the most constructive among the "FANG" stocks on Facebook and Amazon (AMZN), although he adds that the FANG stocks are trading at a multiple that's low by historical standards but high compared to the past eight years. Looking ahead, Graham says slowing ad load growth places greater burden for revenue growth on ad pricing, and data and privacy concerns will linger and may intensify, but he still sees a very constructive case for fundamentals and estimates for the rest of the year and find the valuation reasonable relative to growth. The analyst says he is "comfortable" with his $240 price target, which is based on 26x 2019 EPS.
07/12/18
ADAM
07/12/18
NO CHANGE
Target $2000
ADAM
Buy
Amazon.com price target raised to $2,000 from $1,800 at Canaccord
Canaccord analyst Michael Graham raised its price target on Amazon to $2,000 from $1,800 and maintained a Buy rating, noting strong growth prospects. In a research note to investors, Graham says he is the most constructive among the "FANG" stocks on Amazon and Facebook (FB), although he adds that the FANG stocks are trading at a multiple that's low by historical standards but high compared to the past eight years. Graham thinks his revenue estimate of 38% for Q2 could prove to be conservative, and continues to see Amazon having the most robust and durable growth outlook in the group.
07/13/18
LEHM
07/13/18
NO CHANGE
Target $24
LEHM
Underweight
Twitter valuation 'the primary factor that gives us pause,' says Barclays
Barclays analyst Ross Sandler maintained an Underweight rating and $24 price target on Twitter (TWTR) ahead of its quarterly earnings, telling investors in a research note that while he thinks the company will report "solid" revenue and EBITDA, the company, like Facebook (FB) and Snap (SNAP), will have issues with MAU around GDPR and account clean up. However, he says the company is executing well on its turnaround, checks are pointing to advertisers allocating more to Twitter, which should support mid-20%s O+O ad revenue growth, and says valuation remains the major factor "that gives us pause."
AMZN Amazon.com
$1,797.01

43.96 (2.51%)

07/13/18
LOOP
07/13/18
NO CHANGE
Target $61
LOOP
Buy
United Natural Foods positioned for rise of online grocery, says Loop Capital
Loop Capital analyst Andrew Wolf kept his Buy rating and $61 price target on United Natural Foods, saying the company is best positioned to capitalize on the growing shopping trend of buying groceries online. The analyst notes that the company already supplies Whole Foods (AMZN) and Kroger (KR) with natural and specialty foods as well as health and beauty care goods. Wolf adds that United Natural Foods also offers "backstage capabilities and merchandising curation" that serve the broader market as well as independent natural retailers. The analyst further points to the company's 23% sales increase in e-commerce reported in its most recent quarter.
07/13/18
LEHM
07/13/18
NO CHANGE
Target $1850
LEHM
Overweight
Amazon.com price target raised to $1,850 from $1,700 at Barclays
Barclays analyst Ross Sandler backed an Overweight rating on Amazon and raised his price target to $1,850, telling investors in a research note that the company is likely to report broadly in line revenue and another solid OI quarter in Q2. Sandler, who believes the company may guide conservatively for Q3 on FX and seasonally low OI, says he would add to positions into the print as Amazon has traded up four out of the past seven July earnings, and says Amazon is one of his favorite long-term ideas in consumer internet.
GOOG Alphabet
$1,183.87

29.48 (2.55%)

07/11/18
07/11/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alphabet (GOOGL, GOOG), Facebook (FB), and Spotify (SPOT) were initiated with a Buy at Nomura Instinet while Twitter (TWTR) was initiated with a Reduce. 2. AMC Entertainment (AMC) and Cinemark (CNK) were initiated with an Outperform at Imperial Capital. 3. Keurig Dr Pepper (KDP) initiated with a Hold at Stifel. 4. Myers Industries (MYE) initiated with a Neutral at Baird and JPMorgan. 5. TPG Pace Energy (TPGE) initiated with an Outperform at Northland. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/10/18
BARD
07/10/18
NO CHANGE
Target $1300
BARD
Outperform
Alphabet ad platform enhancement offers more automation, says Baird
Baird analyst Colin Sebastian kept his Outperform rating and $1,300 price target on Alphabet, saying the company's sixth annual Marketing Live conference demonstrated its recently announced core ad platform changes and its ability to "leverage machine learning capabilities". Sebastian notes that the enhancements provide a higher level of automation in ad creation and measurement, making it easier for advertisers to develop campaigns across the company's suite of consumer apps. The analyst adds that moderating growth in traffic acquisition costs as well as its increasing revenue diversification offer further upside potential for Alphabet.
07/12/18
ADAM
07/12/18
NO CHANGE
Target $1050
ADAM
Hold
Alphabet 'fairly valued' ahead of Q2 earnings, says Canaccord
Canaccord analyst Michael Graham said Alphabet is fairly valued ahead of its Q2 earnings report, telling investors in a research note that he believes the company will report "solid" top line performance and is comfortable with his estimate for 26% core Properties revenue growth. He sees core revenue growth staying "comfortable" above 20%, but thinks Alphabet will continue to underperform the FANG complex as gross margin contraction leads to slower EPS growth. With the multiple at a historically "full" level, Graham thinks stock appreciation may be limited. Graham has a Hold rating and $1,050 price target on Alphabet shares.
07/13/18
LEHM
07/13/18
NO CHANGE
Target $1350
LEHM
Overweight
Alphabet price target raised to $1,350 from $1,250 at Barclays
Barclays analyst Ross Sandler reiterated an Overweight rating and raised his price target to $1,350, telling investors in a research note that he would add to positions into Q2, "full stop." Sandler says the recipe for upside is simple, "beat consensus for sites revenue, TAC and operating margin," and he believes this trifecta may happen in Q2 against a muted sentiment backdrop, causing shares to respond positively. He continues to view the risk/reward as attractive.
GOOGL Alphabet Class A
$1,201.91

31.16 (2.66%)

07/11/18
07/11/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. MCDONALD'S CUT TO NEUTRAL: Cleveland Research analyst Steven Gojak downgraded McDonald's (MCD) to Neutral from Buy after his industry checks led him to believe that its comparable sale results in the second half will trend more in-line with consensus expectations. Gojak, who is still modeling Q2 U.S. comp sales growth of 3.7% for McDonald's, which is above the 3.1% consensus growth view, lowered his 2018 U.S. comp estimate to 3.2% from 3.4%, compared to the consensus of 3.1% growth. McDonald's is down 1% in midday trading. NOMURA INITIATES INTERNET SECTOR: Nomura Instinet initiated coverage on the Americas Internet sector. Nomura Instinet initiated Alphabet Class A (GOOGL), Facebook (FB), and Spotify (SPOT) with Buy ratings, and added that Alphabet and Facebook were the best positioned in this newly regulated industry. It initiated Twitter (TWTR) with a Reduce rating, saying that while it is a "stable long-term asset that has something for everyone," the firm believes the market is pricing in "a significant advertising reacceleration that implies a shift in ad spend," while the firm expects "stability instead of a reacceleration of growth." CREDIT SUISSE POSITIVE ON VERIZON, NEGATIVE ON AT&T: Credit Suisse analyst Douglas Mitchelson initiated Verizon (VZ) with an Outperform rating and a price target of $58. The analyst believes Verizon should benefit from its "major $10B cost savings plan, stable capex spending, record low churn, and the benefit of tax reform." Mitchelson also initiated AT&T (T) with an Underperform rating and a price target of $29. Mitchelson said that AT&T will require greater scale and a shift to global direct-to-consumer distribution, stating that the elevated execution risk under its ownership structure and its wireless business look mature with little chance for stabilization in spite of the coming 5G technology. DISNEY VALUATION NOT COMPELLING: Credit Suisse analyst Douglas Mitchelson initiated Disney (DIS) with a Neutral rating and a price target of $114. The analyst noted that the company is "the best positioned traditional media company", but believes the Street has not sufficiently discounted the costs associated with Disney's push into direct-to-consumer streaming services, adding that FY19 will be extra challenging because of high film comps and major theme park project launches.
EXPE Expedia
$127.38

2.2 (1.76%)

06/21/18
WELS
06/21/18
NO CHANGE
Target $160
WELS
Outperform
Expedia price target raised to $160 from $130 at Wells Fargo
Wells Fargo analyst Peter Stabler raised his price target for Expedia (EXPE) to $160 from $130 on cloud migration analysis. Based on company disclosures and his analysis of the TCO of on-premises data center technology versus the Amazon (AMZN) Web Services cloud, the analyst believes that by the end of 2018, Expedia will likely be in the later "innings" of its multi-year cloud technology migration. Stabler reiterates an Outperform rating on Expedia's shares.
06/19/18
RHCO
06/19/18
NO CHANGE
Target $170
RHCO
Buy
Expedia cloud migration to improve operations, says SunTrust
SunTrust analyst Naved Khan kept his Buy rating and $170 price target on Expedia, but noted that his "deep-dive analysis" into the company's cloud migration suggests that it should "boost its operational prowess via improved user experience, more efficient ad spend, meaningful productivity gains and higher conversions." Khan believes that the impact will be felt further through faster growth, with upside of as much as $325M to his above-consensus EBITDA and free cash flows estimated for 2020. The analyst adds that his bullish view on Expedia further reflects positive traction from the company's growth investments.
04/30/18
MKMP
04/30/18
NO CHANGE
Target $122
MKMP
Neutral
Expedia price target raised to $122 from $101 at MKM Partners
MKM Partners analyst Rob Sanderson raised his price target on Expedia to $122 after its Q1 earnings beat, saying room night growth rate of 15% was also solid thanks in part to the timing of Easter relative to last year. Sanderson adds that bookings and revenues are also trending ahead of the company's internal and also consensus expectations. The analyst keeps his Neutral rating on Expedia, noting the company is a "strong number two in an important Internet vertical" and should maintain its in-line performance.
04/27/18
KEYB
04/27/18
NO CHANGE
Target $140
KEYB
Overweight
Expedia results 'solidly better than feared,' says KeyBanc
KeyBanc analyst Brad Erickson Expedia's Q1 results were "solidly better than feared" as he believes third-party data providers' room-night estimates heading into the report "skewed sentiment way too negative." While noting that Q2 room-night comps are tougher, he said comps get easier through the second half and Erickson thinks the setup for hotel additions remains favorable. He raised his price target on Expedia to $140 from $125 and keeps an Overweight rating on Expedia shares.
IAC IAC
$155.55

3.89 (2.56%)

05/30/18
DBAB
05/30/18
INITIATION
Target $18
DBAB
Buy
Deutsche looks for 'home run' with Angi, starts with Buy rating
Deutsche Bank analyst Kunal Madhukar initiated coverage of Angi Homeservices (ANGI) with a Buy rating and $18 price target. In a research note partially titled "Looking for a Home Run," Madhukar says Angi has a large total addressable market with an immediately addressable opportunity of $12B-$16B. Changing demographic trends support online migration and marketplace adoption, as more millennials become homeowners, Madhukar writes. He finds the stock's valuation attractive relative to comps on a growth-adjusted basis. The analyst this morning also assumed coverage of Match Group (MTCH) with a Buy rating and initiated coverage of IAC (IAC) with a Buy rating.
06/11/18
JEFF
06/11/18
NO CHANGE
Target $200
JEFF
Buy
IAC price target raised to $200 from $175 at Jefferies
Jefferies analyst Brent Thill raised his price target for IAC (IAC) to $200 in conjunction with his upgrade this morning of Match Group (MTCH) to Buy from Hold. Trading at just 12 times 2019 EBITDA and a $3B market discount to the company's ownership in Match and Angi Homeservices (ANGI), IAC's valuation looks attractive, Thill tells investors in a research note. He calls the company a top mid cap pick and reiterates a Buy rating on the shares.
05/30/18
DBAB
05/30/18
INITIATION
Target $183
DBAB
Buy
IAC initiated with a Buy at Deutsche Bank
Deutsche Bank started IAC with a Buy rating and $183 price target.
05/11/18
BNCH
05/11/18
NO CHANGE
Target $182
BNCH
Buy
IAC price target raised to $182 from $176 at Benchmark
Benchmark analyst Daniel Kurnos raised his price target on IAC (IAC) to $182 from $176 after its "strong" quarter, which he said was "headlined by blowout revenue and earnings" from Match (MTCH) and continued strong growth at Angi Homeservices (ANGI). He believes risk to IAC from a Facebook (FB) dating challenge seems largely factored in at current levels, Kurnos added.
GDDY GoDaddy
$76.92

1.785 (2.38%)

05/16/18
JMPS
05/16/18
NO CHANGE
Target $84
JMPS
Outperform
GoDaddy price target raised to $84 from $74 at JMP Securities
JMP Securities analyst Ronald Josey noted that GoDaddy's Q1 bookings and revenue came in above his projections as newer product adoption ramps up, international revenue accelerates, and the company showed its cost leverage. Stating that the better than expected Q1 results reaffirm his view that GoDaddy can continue to deliver consistent revenue and cash flow growth, Josey reiterated his Outperform rating on the stock and raised his price target to $84 on GoDaddy.
06/27/18
RHCO
06/27/18
NO CHANGE
Target $30
RHCO
Buy
Web.com price target raised to $30 from $24 at SunTrust
SunTrust analyst Naved Khan raised his price target on Web.com to $30, maintaining his view that the company's agreed acquisition by Siris Capital at $25 per share could generate interest from other potential buyers. Among the potential acquirers, the analyst lists Silver Lake, KKR (KKR), Vector Capital, and GoDaddy (GDDY).
05/09/18
RBCM
05/09/18
NO CHANGE
Target $77
RBCM
Outperform
GoDaddy price target raised to $77 from $69 at RBC Capital
RBC Capital analyst Mark Mahaney raised his price target on GoDaddy to $77 and kept his Outperform rating. The analyst cites a "clean" beat on Q1 results, continued EBITDA margin expansion, and raised FY18 revenue outlook with balance across all three of its segments.
05/09/18
OPCO
05/09/18
NO CHANGE
Target $80
OPCO
Outperform
GoDaddy price target raised to $80 from $70 at Oppenheimer
Oppenheimer analyst Jason Helfstein raised his price target for GoDaddy to $80 from $70 after the company reported "strong" Q1 results and increased FY18 revenue guidance. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

A

Agilent

$64.47

-1.28 (-1.95%)

, AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
American Society of Human Genetics to hold a conference »

ASHG Conference 2018 will…

A

Agilent

$64.47

-1.28 (-1.95%)

AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

RHHBY

Roche

$0.00

(0.00%)

BMRN

BioMarin

$103.31

-0.52 (-0.50%)

BIO

Bio-Rad

$280.96

-3.23 (-1.14%)

MSFT

Microsoft

$108.55

0.01 (0.01%)

ILMN

Illumina

$313.31

-7.98 (-2.48%)

FLDM

Fluidigm

$7.49

-0.45 (-5.67%)

HZNP

Horizon Pharma

$19.07

-0.01 (-0.05%)

NVTA

Invitae

$12.86

-0.23 (-1.76%)

NSTG

NanoString

$15.18

-0.41 (-2.63%)

QGEN

Qiagen

$35.91

0.455 (1.28%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

RTRX

Retrophin

$25.34

0.24 (0.96%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

ARQL

ArQule

$4.33

-0.38 (-8.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 21

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 27

    Nov

  • 28

    Nov

  • 24

    Dec

  • 18

    Feb

  • 03

    Mar

CLBR

Caliburn International

$0.00

(0.00%)

18:27
10/19/18
10/19
18:27
10/19/18
18:27
Syndicate
Caliburn International files registration statement for proposed IPO »

Caliburn International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

18:10
10/19/18
10/19
18:10
10/19/18
18:10
General news
Saudi Arabia says Kashoggi killed after fight broke out in consulate, CNBC says 

Reference Link

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$99.62

2.61 (2.69%)

18:02
10/19/18
10/19
18:02
10/19/18
18:02
Hot Stocks
Celanese raises prices on MIBK, MIBC by EUR120/MT in Europe »

Celanese announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

REGN

Regeneron

$389.94

-5.45 (-1.38%)

, SNY

Sanofi

$44.57

0.12 (0.27%)

17:57
10/19/18
10/19
17:57
10/19/18
17:57
Hot Stocks
Regeneron, Sanofi: FDA approves asthma indication for Dupixent »

Regeneron Pharmaceuticals…

REGN

Regeneron

$389.94

-5.45 (-1.38%)

SNY

Sanofi

$44.57

0.12 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

, XLU

Utilities SPDR

$54.57

0.82 (1.53%)

17:55
10/19/18
10/19
17:55
10/19/18
17:55
General news
Week ending ETF Scorecard: Staples, Real Estate, Utilities lead rebound »

S&P500 SECTORS: …

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

XLU

Utilities SPDR

$54.57

0.82 (1.53%)

IYR

DJ US Real Estate Index Fund

$77.83

0.63 (0.82%)

XLP

Consumer Staples Sector SPDR

$54.72

1.225 (2.29%)

XLY

Consumer Discretionary Sector SPDR

$106.34

-1.06 (-0.99%)

XLB

S&P Select Materials SPDR

$53.13

-0.36 (-0.67%)

XLF

Financial Select Sector

$26.66

0.08 (0.30%)

XLV

Health Care Select Sector SPDR

$91.48

-0.93 (-1.01%)

XLK

Technology Select Sector SPDR

$70.00

-0.04 (-0.06%)

XLI

Industrial Select Sector SPDR

$73.17

-0.31 (-0.42%)

GLD

SPDR Gold Trust

$116.01

0.11 (0.09%)

SLV

iShares Silver Trust

$13.74

0.05 (0.37%)

USO

United States Oil Fund

$14.72

0.155 (1.06%)

UNG

United States Natural Gas Fund

$26.81

0.19 (0.71%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$84.90

0.04 (0.05%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.69

-0.15 (-0.13%)

TLT

iShares 20+ Year Treasury Bond Fund

$113.73

-0.24 (-0.21%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.12

-0.12 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$82.95

-0.035 (-0.04%)

IWD

iShares Russell 1000 Value

$122.17

0.08 (0.07%)

IWF

iShares Russell 1000 Growth

$145.19

-0.5 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSW

International Seaways

$21.51

0.41 (1.94%)

17:53
10/19/18
10/19
17:53
10/19/18
17:53
Syndicate
Breaking Syndicate news story on International Seaways »

International Seaways…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$15.49

0.08 (0.52%)

17:48
10/19/18
10/19
17:48
10/19/18
17:48
Hot Stocks
Monmouth Real Estate acquires industrial building in New Jersey for $85.25M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:38
10/19/18
10/19
17:38
10/19/18
17:38
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:36
10/19/18
10/19
17:36
10/19/18
17:36
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

, LMT

Lockheed Martin

$328.22

0.21 (0.06%)

17:33
10/19/18
10/19
17:33
10/19/18
17:33
Periodicals
Trump to meet CEOs of Boeing, Lockheed Martin, General Dynamics, Reuters reports »

President Donald Trump…

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

LMT

Lockheed Martin

$328.22

0.21 (0.06%)

BA

Boeing

$356.28

-3 (-0.84%)

GD

General Dynamics

$190.43

-0.76 (-0.40%)

BAESY

BAE Systems

$0.00

(0.00%)

HON

Honeywell

$153.49

-1.73 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 30

    Oct

ISR

IsoRay

$0.50

0.0191 (3.98%)

17:25
10/19/18
10/19
17:25
10/19/18
17:25
Syndicate
Breaking Syndicate news story on IsoRay »

IsoRay files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NHS

Neuberger Berman High Yield Strategies Fd

$10.55

-0.015 (-0.14%)

17:06
10/19/18
10/19
17:06
10/19/18
17:06
Hot Stocks
Breaking Hot Stocks news story on Neuberger Berman High Yield Strategies Fd »

Saba Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIOC

Biocept

$2.27

-0.04 (-1.73%)

17:04
10/19/18
10/19
17:04
10/19/18
17:04
Syndicate
Breaking Syndicate news story on Biocept »

Biocept files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZO

AutoZone

$726.10

-4.09 (-0.56%)

17:03
10/19/18
10/19
17:03
10/19/18
17:03
Hot Stocks
AutoZone founder Hyde will not stand for board re-election »

AutoZone announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

SACH

Sachem Capital

$4.33

0.02 (0.46%)

17:03
10/19/18
10/19
17:03
10/19/18
17:03
Syndicate
Breaking Syndicate news story on Sachem Capital »

Sachem Capital files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

16:53
10/19/18
10/19
16:53
10/19/18
16:53
Conference/Events
Mirati Therapeutics to hold a conference call »

Dr. Charles Baum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

SPNE

SeaSpine

$16.58

-0.54 (-3.15%)

16:47
10/19/18
10/19
16:47
10/19/18
16:47
Hot Stocks
Breaking Hot Stocks news story on SeaSpine »

First Light Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$8.76

-0.04 (-0.45%)

16:46
10/19/18
10/19
16:46
10/19/18
16:46
Conference/Events
Epizyme to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

16:40
10/19/18
10/19
16:40
10/19/18
16:40
General news
Breaking General news story on MSCI Italy Index, SPDR S&P 500 ETF Trust, S&P 500 »

Moody's cuts Italy…

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASTC

Astrotech

$2.93

-0.02 (-0.68%)

16:39
10/19/18
10/19
16:39
10/19/18
16:39
Hot Stocks
Breaking Hot Stocks news story on Astrotech »

Winn Interests reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTMX

CytomX Therapeutics

$15.43

-1.075 (-6.52%)

16:38
10/19/18
10/19
16:38
10/19/18
16:38
Conference/Events
CytomX Therapeutics to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

ICLK

iClick Interactive Asia

$3.41

(0.00%)

16:36
10/19/18
10/19
16:36
10/19/18
16:36
Hot Stocks
Breaking Hot Stocks news story on iClick Interactive Asia »

LIM Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.